FDA

November 17 FDA Meeting Could Define the Next Phase for NEO212 Dallas, Texas (www.InvestorsTape.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is heading toward another potentially important regulatory milestone, with the U.S. Food and Drug Administration scheduled to meet with the company on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212,…